Analysis of mutations in the Tk gene of Tk+/- mice treated as neonates with 3′-azido-3′-deoxythymidine (AZT)

Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis

Volumn 547, Issue 1-2, 2004, Pages 63-69

  Mittelstaedt, Roberta A ^a   Von Tungeln, Linda S ^a   Shaddock, Joseph G ^a   Dobrovolsky, Vasily N ^a   Beland, Frederick A ^a   Heflich, Robert H ^a  

^a NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH   (United States)

Author keywords

Loss of heterozygosity; Microsatellites; Transgenic mouse model; Zidovudine

Indexed keywords

ZIDOVUDINE;

ALLELE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHROMOSOME 11; CHROMOSOME LOSS; CHROMOSOME SIZE; CONTROLLED STUDY; DNA FLANKING REGION; EXPERIMENTAL MOUSE; FEMALE; GENE; GENE CONVERSION; GENE DELETION; GENE MUTATION; GENE TK; GENETIC ANALYSIS; GENOTOXICITY; HETEROZYGOSITY LOSS; KNOCKOUT GENE; KNOCKOUT MOUSE; LYMPHOCYTE CLONE; MALE; MICROSATELLITE MARKER; MITOTIC RECOMBINATION; MOUSE; NEWBORN; NONHUMAN; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE;

ALLELES; ANIMALS; ANIMALS, NEWBORN; ANTI-HIV AGENTS; CHROMOSOMES; CLONE CELLS; DNA MUTATIONAL ANALYSIS; GENE DELETION; HETEROZYGOTE; LOSS OF HETEROZYGOSITY; LYMPHOCYTES; MICE; MICE, TRANSGENIC; MICROSATELLITE REPEATS; MUTATION; RECOMBINATION, GENETIC; THYMIDINE KINASE; ZIDOVUDINE;

HUMAN IMMUNODEFICIENCY VIRUS; MUS MUSCULUS;

EID: 1542375451     PISSN: 00275107     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mrfmmm.2003.12.008     Document Type: Article

References (18)

1. Connor E.M., Sperling R.S., Gelber R., Kiselev P., Scott G., O'Sullivan M.J., Van Dyke R.B., Bey M., Shearer W., Jacobson R.L. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. N. Engl. J. Med. 331:1994;1173-1180.
2. Sperling R.S., Shapiro D.E., Combs R.W., Todd J.A., Herman S.A., McSherry G.D., O'Sullivan M.J., Van Dyke R.B., Jimenez E., Rouzioux C., Flynn P.M., Sullivan J.L. Maternal viral load. N. Engl. J. Med. 335:1996;1621-1629.
3. Public Health Service Task Force Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV-1 Transmission in the United States, 4 February 2002, http://www.hivatis.org.
4. Olivero O.A., Anderson L.M., Diwan B.A., Haines D.C., Harbaugh S.W., Moskal T.J., Jones A.B., Rice J.M., Riggs C.W., Logsdon D., Yuspa S.H., Poirier M.C. Transplacental effects of 3′-azido-2′3′-dideoxythymidine (AZT): tumorigenicity in mice and genotoxicity in mice and monkeys. J. Natl. Cancer Inst. 89:1997;1602-1608.
5. Diwan B.A., Riggs C.W., Logsdon D., Haines D.C., Olivero O.A., Rice J.M., Yuspa S.H., Poirier M.C., Anderson L.M. Multiorgan transplacental and neonatal carcinogenicity of 3′-azido-3′-deoxythymidine in mice. Toxicol. Appl. Pharmacol. 161:1999;82-99.
6. +/- mice treated neonatally with zidovudine and lamivudine. Carcinogenesis. 23:2002;1427-1432.
7. Furman P.A., Fyre J.A., St. Clair M.H., Weinhold K., Rideout J.L., Freeman G.A., Lehrman S.N., Bolognesi D.P., Broder S., Mitsuya H., Barry D.W. Phosphorylation of 3′-azido-3′-deoxythymidine and selective interaction of the 5′-triphosphate with human immunodeficiency virus reverse transcriptase. Proc. Natl. Acad. Sci. U.S.A. 83:1986;8333-8337.
8. Adams W.T., Skopek T.R. Statistical test for the comparison of samples from mutational spectra. J. Mol. Biol. 194:1987;391-396.
9. +/- mice. Environ. Mol. Mutagen. 35:2000;150-157.
10. Wijnhoven S.W.P., Sonneveld E., Kool H.J.M., vanTeijlingen C.M.M., Vrieling H. Chemical carcinogens induce varying patterns of LOH in mouse T-lymphocytes. Carcinogenesis. 24:2003;139-144.
11. Meng Q., Su T., Olivero O.A., Poirier M.C., Shi X., Ding X., Walker V.E. Relationships between DNA incorporation, mutant frequency, and loss of heterozygosity at the TK locus in human lymphoblastoid cells exposed to 3′-azido-3′-deoxythymidine. Toxicol. Sci. 54:2000;322-329.
12. Meng Q., Grosovsky A.J., Shi X., Walker V.E. Mutagenicity and loss of heterozygosity at the APRT locus in human lymphoblastoid cells exposed to 3′-azido-3′-deoxythymidine. Mutagenesis. 15:2000;405-410.
13. Sussman H.E., Olivero O.A., Meng Q., Pietras S.M., Poirier S.M., O'Neill J.P., Finette B.A., Bauer M.J., Walker V.E. Genotoxicity of 3′-azido- 3′-deoxythymidine in the human lymphoblastoid cell line, TK6: relationships between DNA incorporation, mutant frequency and spectrum of deletion mutations in HPRT. Mutation Res. 429:1999;249-259.
14. Wijnhoven S.W.P., VanSloun P.P.H., Kool H.J.M., Weeda G., Slater R., Lohman P.H.M., vanZeeland A.A., Vrieling H. Carcinogen-induced loss of heterozygosity at the Aprt locus in somatic cells of the mouse. Proc. Natl. Acad. Sci. U.S.A. 95:1998;13759-13764.
15. Turker M.S., Gage B.M., Rose J.A., Elroy D., Ponomareva O.N., Stambrook P.J., Tischfield J.A. A novel signature mutation for oxidative damage resembles a mutational pattern found commonly in human cancers. Cancer Res. 59:1999;1837-1839.
16. Ponomareva O.N., Rose J.A., Lasarev M., Rasey J., Turker M.S. Tissue-specific deletion and discontinuous loss of heterozygosity are signatures for the mutagenic effects of ionizing radiation in solid tissues. Cancer Res. 62:2002;1518-1523.
17. de la Asuncion J.G., del Olmo M.L., Sastre J., Millan A., Pellin A., Pallardo F.V., Vina J. AZT treatment induces molecular and ultrastructural oxidative damage to muscle mitochondria. J. Clin. Invest. 102:1998;4-9.
18. Bialkowska A., Bialkowski K., Gerschenson M., Diwan B.A., Jones A.B., Olivero O.A., Poirier M.C., Anderson L.M., Kasprzak K.S., Sipowicz M.A. Oxidative DNA damage in fetal tissues after transplacental exposure to 3′-azido-3′-deoxythymidine (AZT). Carcinogenesis. 21:2000;1059-1062.